Paper Details

  1. Home
  2. Paper Details

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.

Author: ChiarabiniThibault, DevredInès, KayembeKick, LacombeKarine, Lambert-NiclotSidonie, MeyohasMarie-Caroline, RougierHayette, ShingaBruce Wuembulua, ValinNadia

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study compares the completion rates of doravirine/tenofovir disoproxil fumarate/lamivudine (DOR/3TC/TDF) and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/c/FTC/TAF) for HIV post-exposure prophylaxis (PEP). The study found that DOR/3TC/TDF had a similar safety profile to EVG/c/FTC/TAF, with a comparable completion rate and no cases of seroconversion. DOR/3TC/TDF may be a cost-effective treatment option for PEP in the context of HIV-exposure accidents.
Paper Details　
Original Abstract of the Article :
HIV post- exposure prophylaxis (PEP) is a prevention tool for individuals with a recent potential exposure to HIV. Doravirine has been available since 2019 in combination with tenofovir disoproxil fumarate and lamivudine and has not been evaluated as a PEP. DOR/3TC/TDF is our department's most commo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478445/

データ提供：米国国立医学図書館（NLM）

Exploring New Frontiers: Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate for HIV Post-Exposure Prophylaxis

The battle against HIV continues with the constant exploration of new frontiers in prevention and treatment. This study delves into the effectiveness of a new HIV post-exposure prophylaxis (PEP) regimen, doravirine-lamivudine-tenofovir disoproxil fumarate (DOR/3TC/TDF). The authors conducted a retrospective observational study to evaluate the completion rate, seroconversion rate, and side effects of DOR/3TC/TDF compared to the previously used regimen, elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide (EVG/c/FTC/TAF). The findings suggest that DOR/3TC/TDF has a similar safety profile and completion rate to EVG/c/FTC/TAF, making it a potentially cost-effective alternative for HIV-exposure accidents.

A New Oasis in the Desert of HIV Prevention: DOR/3TC/TDF Emerges as a Promising Option

The research highlights the potential of DOR/3TC/TDF as a valuable addition to the arsenal of HIV prevention tools. The study demonstrates its comparable safety profile and completion rate to the previously used regimen, suggesting a promising alternative for individuals who have experienced HIV exposure.

Combating HIV: A Journey Towards Effective Prevention and Treatment

This research is a testament to the ongoing quest for more effective and accessible HIV prevention and treatment options. The findings offer a glimmer of hope in the fight against this global health challenge, providing a potentially cost-effective alternative for individuals facing HIV exposure.

Dr. Camel's Conclusion

This research sheds light on the potential of DOR/3TC/TDF as a promising new approach for HIV post-exposure prophylaxis. The study's findings offer a valuable addition to the tools available for preventing HIV transmission, particularly in cases of accidental exposure. As we continue our journey to combat HIV, this discovery serves as a reminder of the ongoing search for innovative solutions and the potential for a healthier future.

Date :
  1. Date Completed 2023-09-06
  2. Date Revised 2023-11-21
Further Info :

Pubmed ID

37667182

DOI: Digital Object Identifier

PMC10478445

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.